Fubon NYSE FactSet Global Genomics and Immuno Biopharma Exchange Traded Fund seeks investment results that closely track the performance of NYSE® FactSet® Global Genomics and Immuno Biopharma Index, before fees and expenses.
The NYSE® FactSet® Global Genomics and Immuno Biopharma Index is a rules-based equity benchmark designed to track the performance of globally listed companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
The NYSE® FactSet® Global Genomics and Immuno Biopharma Index is compiled utilizing a methodology, RBICS (Revere Business Industry Classification System) classifications, and FactSet Supply Chain Relationships licensed from FactSet.
Principal Investment Strategy
Fubon Global Genomics and Immuno Biopharma ETF would allocate over 90% AUM in the constituents of NYSE® FactSet® Global Genomics and Immuno Biopharma Price Return Index and follow the index rebalance in order to deliver the corresponding performance of its underlying index.
Top Ten Holdings
||INTELLIA THERAPEUTICS INC
||REGENERON PHARMACEUTICALS INC
||SAREPTA THERAPEUTICS INC
||GILEAD SCIENCES INC
||BLUEPRINT MEDICINES CORP
Source: ICE DATA INDICES,LLC Data as of 2021.11.30